Assessment of response to therapy in hepatocellular carcinoma

about

Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma.

P2860

Q37373034-B4108E45-17E9-447B-ADB7-D94A4D2E9CE5

P2860

Assessment of response to therapy in hepatocellular carcinoma

Item

http://www.wikidata.org/entity/Q33560982

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Assessment of response to therapy in hepatocellular carcinoma

@ast

Assessment of response to therapy in hepatocellular carcinoma

@en

Assessment of response to therapy in hepatocellular carcinoma.

@nl

type

Item

label

Assessment of response to therapy in hepatocellular carcinoma

@ast

Assessment of response to therapy in hepatocellular carcinoma

@en

Assessment of response to therapy in hepatocellular carcinoma.

@nl

prefLabel

Assessment of response to therapy in hepatocellular carcinoma

@ast

Assessment of response to therapy in hepatocellular carcinoma

@en

Assessment of response to therapy in hepatocellular carcinoma.

@nl

P1476

Assessment of response to therapy in hepatocellular carcinoma

@en

P2093

Denise Harnois

http://www.w3.org/2001/XMLSchema#string

Tushar Patel

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization.

Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization

Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma

Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.

Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.

Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy

P304

130-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/07853890.2014.891355

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24716738

http://www.w3.org/2001/XMLSchema#string

P932

4008698

http://www.w3.org/2001/XMLSchema#string

Assessment of response to therapy in hepatocellular carcinoma

about

P2860

P2860

Assessment of response to therapy in hepatocellular carcinoma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932